USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ADVANCED TARGETING SYSTEMS, INC.
Address:
10451 Roselle St #300
SAN DIEGO, CA 92121
Phone:
N/A
URL:
EIN:
330632253
DUNS:
010081909
Number of Employees:
9
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,007,606.00 13
SBIR Phase II $4,616,812.00 5

Award List:

Specific Tool for Modeling Neuronal Degeneration

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$96,844.00
Agency:
HHS
Principal Investigator:
Douglas Lappi
Abstract:
Alzheimer's disease (AD) is a common, devastating neurodegenerative disorder characterized by progrcognitive decline. Loss of the cholinergic innervation of limbic structures and the neocortex occursin patients with AD. The degree of cognitive decline has been correlated to the extent of… More

NEW TOOL FOR BASIC NEUROBIOLOGICAL RESEARCH

Award Year / Program / Phase:
1996 / SBIR / Phase I
Award Amount:
$99,997.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

NEW TOOL FOR BASIC NEUROBIOLOGICAL RESEARCH

Award Year / Program / Phase:
1998 / SBIR / Phase II
Award Amount:
$749,317.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

TOOLS FOR THE DISSECTION OF PAIN TRANSMISSION PATHWAYS

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Douglas A. Lappi
Abstract:
N/a

MAB'S TO TARGET SPECIFIC NEURONAL POPULATIONS

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$113,227.00
Agency:
HHS
Principal Investigator:
Douglas A. Lappi
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Douglas A. Lappi
Abstract:
N/a

Targeting Neurons Involved in Chronic Pain Transmission

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$133,547.00
Agency:
HHS
Principal Investigator:
Douglas A. Lappi
Abstract:
DESCRIPTION (Adapted from applicant's abstract): Chronic pain is an enormous problem in the United States: it is estimated that 30 to 100 million people suffer from it. Often, current treatments are ineffective and the population of sufferers is often described as… More

TOXICOLOGY/SAFETY STUDIES OF A CHRONIC PAIN THERAPEUTIC

Award Year / Program / Phase:
2001 / SBIR / Phase II
Award Amount:
$397,984.00
Agency:
HHS
Principal Investigator:
Douglas A. Lappi
Abstract:
N/a

TOXICOLOGY/SAFETY STUDIES OF A CHRONIC PAIN THERAPEUTIC

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Douglas A. Lappi
Abstract:
N/a

A Specific Tool for Targeting Neurodegeneration

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Douglas A. Lappi
Abstract:
DESCRIPTION: (Adapted from the Applicant's Abstract) The Mouse is the species of choice for many neuroscientists because of well-characterized molecular biology and chemistry of its brain, the recent widespread use of transgenic and knockout techniques, and the low cost and… More

A Specific Tool for Targeting Neurodegeneration

Award Year / Program / Phase:
2001 / SBIR / Phase II
Award Amount:
$282,235.00
Agency:
HHS
Principal Investigator:
Douglas A. Lappi
Abstract:
DESCRIPTION: (Adapted from the Applicant's Abstract) The Mouse is the species of choice for many neuroscientists because of well-characterized molecular biology and chemistry of its brain, the recent widespread use of transgenic and knockout techniques, and the low cost and… More

Drug Development of a Chronic Pain Therapeutic

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): SP-SAP, a conjugate between the peptide neurotransmitter substance P, and the ribosome-inactivating protein, saporin, has been shown, through previous NIH funding, to ablate chronic pain transmission in several rat models. Importantly, acute, reflexive pain… More

Drug Development of a Chronic Pain Therapeutic

Award Year / Program / Phase:
2003 / SBIR / Phase II
Award Amount:
$2,388,923.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): SP-SAP, a conjugate between the peptide neurotransmitter substance P, and the ribosome-inactivating protein, saporin, has been shown, through previous NIH funding, to ablate chronic pain transmission in several rat models. Importantly, acute, reflexive pain… More

Monoclonal Antibodies to Target Neuronal Populations

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

Monoclonal Antibodies to Target Neuronal Populations

Award Year / Program / Phase:
2003 / SBIR / Phase II
Award Amount:
$798,353.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

Inhibition of Neurotransmission in Specific Neuronal Populations

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$114,336.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): In extensive work over the last decade, it has become clear that biologically active molecules can be inserted into specific cell types through targeting to molecules on the cell surface. It is here proposed to direct this technology to specific neuronal cell… More

Selective Activation in Specific Neuronal Populations

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$99,175.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Selective Activation in Specific Neuronal Populations Summary: Molecules targeted towards cell surface markers have been used for years to identify specific cell types. It has been demonstrated over the course of the pa st decade that biologically-active… More

Targeting a Poor Prognosis Marker for Tumor Therapy

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$150,480.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Targeting a Poor Prognosis Marker for Tumor Therapy Summary The purpose of this proposal is to develop a medical treatment for the elimination of metastatic cancers. According to the National Cancer Institute, the s urvival rate for many types of cancer has… More